A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication

NCT02089581 | Completed Phase 1

• 2 other identifiers: HMX15082013-005523-16
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 2

Brief Summary

To determine whether two new oral formulations of a strong pain killer release the drug into the body in a similar pattern as the already marketed reference capsule formulation with or without food.

Conditions

Pain

Keywords

Healthy Volunteer; Pharmacokinetics; Bioequivalence

Outcome Measures

Primary Outcomes (2)

• Assess the pharmacokinetics and potential for bioequivalence of two novel formulations

  Areas under the plasma concentration-time curve calculated to the last measurable concentration (AUCt) will be calculated using the linear trapezoidal method. Where possible, the terminal phase rate constants will be estimated using those points determined to be in the terminal log-linear phase. Half-lives (t1/2Z) will be determined from the ratio of ln 2 to LambdaZ. The areas under the plasma concentration-time curve between the last measured point and infinity will be calculated from the ratio of the final observed plasma concentration (Clast) to LambdaZ. This will be added to the AUCt to yield the area under the plasma concentration-time curve between the time of administration and infinity (AUCINF).

  Up to 32 hours

• The primary objective of the definitive phase is to assess bioequivalence of one or two experimental capsule formulations

  Areas under the plasma concentration-time curve calculated to the last measurable concentration (AUCt) will be calculated using the linear trapezoidal method. Where possible, the terminal phase rate constants will be estimated using those points determined to be in the terminal log-linear phase. Half-lives (t1/2Z) will be determined from the ratio of ln 2 to LambdaZ. The areas under the plasma concentration-time curve between the last measured point and infinity will be calculated from the ratio of the final observed plasma concentration (Clast) to LambdaZ. This will be added to the AUCt to yield the area under the plasma concentration-time curve between the time of administration and infinity (AUCINF). Drug Concentration Measurements: Pre-dose on the first day of each study period, and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 16, 24 and 32 hours after dosing (19 samples per study period).

  32 hours

Secondary Outcomes (1)

• Assess the safety and tolerability of two experimental formulations of Tablet and Capsule in a fasted and fed state by the collection of adverse events, vital signs, clinical laboratory results and ECGs

  Up to 32 hours

Study Arms (4)

Drug

ACTIVE COMPARATOR

MR2XXX

Drug: Active comparator MR2XXX

MRXXX

EXPERIMENTAL

MRXXX capsule 12 hourly

Drug: MRXXX

MR1XXX

EXPERIMENTAL

MR1XXX capsule, 12 hourly

Drug: MR1XXX

Experimental

EXPERIMENTAL

Experimental Fed

Drug: MRXXX and MR1XXX

Interventions

Active comparator MR2XXX DRUG

comparison of two new oral formulations with existing formulation

Also known as: MR2XXX

Drug

MRXXX DRUG

MRXXX

Also known as: Experimental capsule formulation compared to marketed reference product

MRXXX

MR1XXX DRUG

MR1XXX

MRXXX and MR1XXX DRUG

MRXXX and MR1XXX in fed and fasted state

Also known as: MRXXX and MR1XXX in fed and fasted state

Experimental

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female subjects aged 18 to 55 inclusive.
• Female subjects who are sexually active or become sexually active must be willing to use highly effective methods of contraception throughout the study. A highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as sterilisation, implants, injectables, combined oral contraceptives, some IUDs (Intrauterine Device), or vasectomised partner.
• Female subjects less than one year post-menopausal must have a negative serum pregnancy test and be non-lactating.
• Female subjects who have been post-menopausal for \> 1 year and have elevated serum follicle-stimulating hormone (FSH) or are treated with hormone replacement therapy (HRT).
• Male subjects must be willing to use contraception with their partners throughout the study and for 30 days after completion of the study and agree to inform the Investigator if their partner becomes pregnant during this time.
• Body weight ranging from 55 to 100 kg and a BMI ≥ 18.5 and ≤ 29.9.
• Healthy and free of significant abnormal findings as determined by medical history, physical examination, vital signs, laboratory tests and ECG.
• Willing to eat all the food supplied throughout the study.
• The subject's primary care physician has confirmed within the last 12 months that there is nothing in their medical history that would preclude their enrolment into a clinical study.

You may not qualify if:

• Any history of drug or alcohol abuse.
• Any history of conditions that might interfere with drug absorption, distribution, metabolism or excretion.
• Use of opioid or opioid antagonist-containing medication in the past 30 days.
• Any history of frequent nausea or vomiting regardless of etiology.
• Any history of seizures or symptomatic head trauma.
• Paralytic ileus, respiratory depression, hypoxia or elevated carbon dioxide levels in the blood.
• Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
• Subjects must not participate in both the pilot and definitive phase or in more than one Cohort.
• Any significant illness during the 4 weeks preceding entry into this study.
• Use of any medication including vitamins, herbal and/or mineral supplements during the 7 days preceding the initial dose or during the course of this study (with the exception of the continued use of HRT and contraceptives). Note: subjects taking oral contraceptives containing CYP3A4 inhibitors such as gestodene should be excluded as this may lead to elevated plasma concentrations.

Sponsors & Collaborators

• Mundipharma Research Limited: lead

Study Sites (2)

Biokinetic

Belfast, United Kingdom

Location

Unknown Facility

Belfast, United Kingdom

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2014
• First Posted: March 18, 2014
• Study Start: April 1, 2014
• Primary Completion: May 1, 2014
• Study Completion: July 1, 2015
• Last Updated: September 28, 2015

Record last verified: 2015-09

Locations

GB (2)